Helmy M. Guirgis, MD, PhD

Helmy M. Guirgis, MD, PhD, is a hematologist-oncologist whose academic work has been associated with the University of California, Irvine. His research focuses on the clinical value, affordability, and proportional benefit of anticancer therapies, particularly in lung cancer and other metastatic diseases. Guirgis has developed comparative approaches that examine survival gains alongside treatment duration, toxicity, quality of life, and drug cost. His publications address immune checkpoint inhibitors, targeted therapies, monoclonal antibodies, prostate cancer treatment, and methods for evaluating cost relative to patient outcomes. Through this work, he contributes a health-economic perspective to oncology, emphasizing transparent assessment of treatment value and sustainable access to modern cancer medicines.